keyword
MENU ▼
Read by QxMD icon Read
search

Omalizumab atopic dermatitis

keyword
https://www.readbyqxmd.com/read/28535776/the-role-of-anti-ige-omalizumab-xolair-in-the-management-of-severe-recalcitrant-paediatric-atopic-eczema-adapt-statistical-analysis-plan
#1
Tao Chen, Susan Chan, Gideon Lack, Suzie Cro, Victoria R Cornelius
BACKGROUND: The Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT) is a trial to determine the clinical efficacy and safety of omalizumab for children with severe atopic eczema. This article describes the detailed statistical analysis plan for the ADAPT as an update to the published protocol and is submitted prior to knowing all outcomes. METHOD AND DESIGN: The ADAPT is a randomised, double-blind, placebo-controlled trial with a primary objective to determine whether anti-IgE reduces eczema severity as assessed by the validated eczema score (objective SCORAD) after 24 weeks of treatment in children with severe eczema...
May 23, 2017: Trials
https://www.readbyqxmd.com/read/28500690/tumour-necrosis-factor-receptor-associated-periodic-syndrome-mimicking-chronic-spontaneous-urticaria
#2
LETTER
S Aurich, J C Simon, R Treudler
No abstract text is available yet for this article.
May 13, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28492605/severe-refractory-atopic-dermatitis-with-elevated-serum-ige-treated-with-omalizumab
#3
Stephen A Switlyk, Andrea L Taylor, Erich M Gaertner
No abstract text is available yet for this article.
April 2017: Cutis; Cutaneous Medicine for the Practitioner
https://www.readbyqxmd.com/read/28366479/biologic-therapy-in-the-treatment-of-chronic-skin-disorders
#4
REVIEW
James M Fernandez, Anthony P Fernandez, David M Lang
Understanding of the immunologic pathways involved in the pathogenesis of skin-related diseases is constantly advancing. Several biologic agents play important therapeutic roles for management of patients with chronic urticaria, atopic dermatitis, and psoriasis, particularly omalizumab for antihistamine-resistant chronic urticaria, interleukin (IL)-1 inhibitors for cryopyrin-associated periodic syndrome and Schnitzler syndrome, dupilumab for recalcitrant atopic dermatitis, and IL-17 inhibitors for psoriasis...
May 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28350555/apheresis-in-food-allergies
#5
Lamia Dahdah, Giovanna Leone, Mariacristina Artesani, Carla Riccardi, Oscar Mazzina
PURPOSE OF REVIEW: The prevalence of IgE-mediated food allergy and anaphylaxis has risen rapidly in developed countries, and countries with rapid industrialization may follow. Therapies include elimination diets, Oral ImmunoTherapy, and the administration of biologics, but high serum IgE levels may preclude their use. Consequently, decreasing IgE becomes a rational approach and could be obtained by immunoapheresis. The aim of this review is to evaluate the rationale and advantages of immunoapheresis...
June 2017: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28330497/atopic-dermatitis-anti-ige-paediatric-trial-adapt-the-role-of-anti-ige-in-severe-paediatric-eczema-study-protocol-for-a-randomised-controlled-trial
#6
Susan Chan, Victoria Cornelius, Tao Chen, Suzana Radulovic, Mandy Wan, Rahi Jahan, Gideon Lack
BACKGROUND: The evidence for systemic treatments for severe childhood eczema is limited and largely based on extrapolation of data from adult studies. Current therapies are often immunosuppressant and may be associated with both short- and long-term side effects. There is increasing in vitro and murine-model evidence for the role of IgE in the immunopathogenesis of atopic eczema. The aim of the study is to assess whether anti-IgE treatment (omalizumab) improves eczema, compared to placebo...
March 22, 2017: Trials
https://www.readbyqxmd.com/read/27759482/dermatologic-uses-of-omalizumabtitle
#7
Justin C Chia, P Régine Mydlarski
PURPOSE: Omalizumab is a recombinant humanized monoclonal antibody that inhibits the binding of immunoglobulin E (IgE) to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Omalizumab has been approved for use in asthma, and new reports show promise in a variety of dermatologic diseases. Herein, we review the literature on omalizumab in dermatology and discuss the safety, efficacy and mechanisms of action for this emerging therapy. MATERIALS AND METHODS: PubMED, MEDLINE and Embase databases were searched for the period 1 January 1990 to 1 September 2016...
June 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/27694038/targeting-mast-cells-uncovering-prolific-therapeutic-role-in-myriad-diseases
#8
REVIEW
Jatinder Singh, Ramanpreet Shah, Dhandeep Singh
The mast cells are integral part of immune system and they have pleiotropic physiological functions in our body. Any type of abnormal stimuli causes the mast cells receptors to spur the otherwise innocuous mast cells to degranulate and release inflammatory mediators like histamine, cytokines, chemokines and prostaglandins. These mediators are involved in various diseases like allergy, asthma, mastocytosis, cardiovascular disorders, etc. Herein, we describe the receptors involved in degranulation of mast cells and are broadly divided into four categories: G-protein coupled receptors, ligand gated ion channels, immunoreceptors and pattern recognition receptors...
November 2016: International Immunopharmacology
https://www.readbyqxmd.com/read/27613653/novel-biologicals-for-the-treatment-of-allergic-diseases-and-asthma
#9
REVIEW
Hern-Tze Tina Tan, Kazunari Sugita, Cezmi A Akdis
PURPOSE OF REVIEW: The development of biological therapies has rapidly progressed during the last few years, and major advances were reported for the treatment of allergic diseases, such as atopic dermatitis, allergic rhinitis, urticaria, food allergy, and asthma. Here, we review biologicals targeting the type 2 immune response involving Th2 cells, type 2 innate lymphoid cells, natural killer T cells, mast cells, basophils, and epithelial cells, such as IL-4, IL-5, IL-13, IL-31, tumor necrosis factor alpha (TNF-α), and thymic stromal lymphopoietin (TSLP)...
October 2016: Current Allergy and Asthma Reports
https://www.readbyqxmd.com/read/27543070/efficacy-of-omalizumab-in-patients-with-atopic-dermatitis-a%C3%A2-systematic-review-and-meta-analysis
#10
Hsiao-Han Wang, Yu-Chuan Li, Yu-Chen Huang
No abstract text is available yet for this article.
December 2016: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/27337170/omalizumab-for-atopic-dermatitis-case-series-and-a-systematic-review-of-the-literature
#11
REVIEW
Jesper Grønlund Holm, Tove Agner, Carsten Sand, Simon Francis Thomsen
Omalizumab is a recombinant humanized monoclonal antibody targeting the high-affinity Fc receptor of IgE, registered for the treatment of chronic spontaneous urticaria and severe allergic asthma. We present a case series of nine patients with atopic dermatitis (AD) treated off-label with omalizumab and a systematic review of the existing literature. Patients were selected consecutively from a tertiary dermatological referral center during a 5-year period. All patients were treated with omalizumab at a starting dose of 300 mg subcutaneously every 4 weeks...
January 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/27090058/treating-ige-mediated-diseases-via-targeting-ige-expressing-b-cells-using-an-anti-c%C3%AE%C2%B5mx-antibody
#12
REVIEW
Sean S Liour, Andrew Tom, Yueh-Hsuan Chan, Tse Wen Chang
Targeting the IgE pathway is a clinically validated strategy for treating IgE-mediated diseases. Omalizumab, an anti-IgE antibody, which binds to free IgE and prevents the binding of IgE to FcεRI on mast cells and basophils has been approved for severe persistent allergic asthma and chronic spontaneous (idiopathic) urticaria. The therapeutic efficacy of anti-IgE has also been reported in allergic rhinitis, allergic bronchopulmonary aspergillosis, latex allergy, atopic dermatitis, allergic urticaria, anaphylaxis, and others...
August 2016: Pediatric Allergy and Immunology
https://www.readbyqxmd.com/read/26620589/monoclonal-antibodies-the-new-magic-bullets-for-allergy-iuphar-review-17
#13
REVIEW
N Landolina, F Levi-Schaffer
Allergic diseases and conditions are widespread and their incidence is on the increase. They are characterized by the activation of mast cells resident in tissues and the consequent infiltration and stimulation of several inflammatory cells, predominantly eosinophils. Cell-cell cross-talk and the release of mediators are responsible for the symptoms and for the modulation of the response. The gold standard of therapeutic intervention is still glucocorticosteroids, although they are not effective in all patients and may cause numerous side effects...
March 2016: British Journal of Pharmacology
https://www.readbyqxmd.com/read/26607958/beyond-psoriasis-novel-uses-for-biologic-response-modifiers-in-pediatric-dermatology
#14
REVIEW
Fernanda Bellodi-Schmidt, Kara N Shah
Dermatologists have witnessed the increasing availability of novel biologic response modifiers for the treatment of inflammatory and autoimmune diseases in recent years. The most common dermatologic indication for the use of biologic response modifiers in adults is psoriasis, but the U.S. Food and Drug Administration has not approved any of these agents for use in any dermatologic disease in children with the exception of omalizumab, and as such, use in this population is considered off-label. In this review, we focus on the use of these agents in children to treat inflammatory skin diseases other than psoriasis, including atopic dermatitis, hidradenitis suppurativa, pemphigus vulgaris, bullous pemphigoid, and toxic epidermal necrolysis, with an emphasis on the use of etanercept, infliximab, rituximab, omalizumab, and ustekinumab...
January 2016: Pediatric Dermatology
https://www.readbyqxmd.com/read/26059424/targeting-ige-in-severe-atopic-dermatitis-with-a-combination-of-immunoadsorption-and-omalizumab
#15
Alexander Zink, Anna Gensbaur, Michael Zirbs, Florian Seifert, Isabel Leon Suarez, Vagkan Mourantchanian, Stephan Weidinger, Martin Mempel, Johannes Ring, Markus Ollert
Patients with atopic dermatitis (AD) tend to have greatly elevated levels of serum immunoglobulin E (IgE). However, the role of IgE in the pathogenesis of AD is debated. This investigator-initiated open-label pilot study evaluates an anti-IgE-treatment approach by combining extracorporeal immunoadsorption and anti-IgE antibody omalizumab in 10 patients with severe, therapy-refractory AD. IgE levels decreased after immunoadsorption and decreased continuously in all patients during anti-IgE therapy. The reverse trend was observed during 6 months follow-up without treatment...
January 2016: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/26048266/off-label-uses-of-omalizumab
#16
REVIEW
David El-Qutob
The off-label use of medicines is a common and extensive clinical practice. Omalizumab has been licensed for use in severe allergic asthma and chronic urticaria. Omalizumab dosing was based on body weight and baseline serum IgE concentration. All patients are required to have a baseline IgE between 30 and 700 IU/ml and body weight not more than 150 kg. The use of off-label drugs may lead to several problems including adverse effects and an increased risk/benefit balance. In this article, there are summarized off-label uses of omalizumab in the last recent years in diseases in which IgE maybe or certainly has a corner role such as allergic rhinitis, allergic bronchopulmonary aspergillosis, anaphylaxis, keratoconjunctivitis, food allergy, drug allergy, urticaria, angioedema, non-atopic asthma, atopic dermatitis, nasal polyps, Churg-Strauss syndrome, eosinophilic otitis media, chronic rhinosinusitis, bullous pemphigoid, contact dermatitis, and others...
February 2016: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/26021140/-dermatological-implications-of-omalizumab-an-anti-ige-antibody
#17
Julie Di Lucca-Chrisment
The Omalizumab is a humanized anti-IgE monoclonal for which the extensive experience of its use in allergic asthma confirms its very good tolerance. By frequent association with asthma, atopic dermatitis is the first dermatological field has having tested this biological agent, unfortunately without convincing study at present. Surprisingly, this anti-IgE antibody is also reported as effective in certain non-IgE-mediated diseases including several dermatological indications. Since 2014, the Omalizumab got the indication in Europe for the treatment of chronic spontaneous urticaria after escapement to antihistamines...
April 1, 2015: Revue Médicale Suisse
https://www.readbyqxmd.com/read/25609342/the-use-of-anti-ige-therapy-beyond-allergic-asthma
#18
REVIEW
Jeffrey R Stokes, Thomas B Casale
Omalizumab is a monoclonal anti-IgE antibody that has been used to treat allergic asthma for over a decade. The use of omalizumab to treat other diseases has largely been limited to case reports until the recently reported large multicenter studies that have established omalizumab as an effective treatment option for chronic spontaneous urticaria. The utility of omalizumab to treat nonallergic asthma and allergic rhinitis and the added safety and therapeutic benefits in combination with allergen immunotherapy have been demonstrated in placebo-controlled trials...
March 2015: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/25578818/omalizumab-for-difficult-to-treat-dermatological-conditions-clinical-and-immunological-features-from-a-retrospective-real-life-experience
#19
Ciro Romano, Ausilia Sellitto, Umberto De Fanis, Antonella Balestrieri, Alfonso Savoia, Salvatore Abbadessa, Corrado Astarita, Giacomo Lucivero
BACKGROUND: Omalizumab, a therapeutic monoclonal antibody specific for human IgE, has thus far been used as add-on therapy for moderate-to-severe allergic asthma in adults and children. OBJECTIVE: The objective of this study was to test omalizumab efficacy in other conditions in which the IgE-mast cell axis is supposed to play a role. METHODS: Nine patients with dermatological manifestations possibly related to activation of the IgE-mast cell axis (six chronic spontaneous urticaria and three atopic dermatitis patients) were administered off-label omalizumab because of refractoriness to standard therapy...
March 2015: Clinical Drug Investigation
https://www.readbyqxmd.com/read/25363953/immunologic-effects-of-omalizumab-in-children-with-severe-refractory-atopic-dermatitis-a-randomized-placebo-controlled-clinical-trial
#20
Doerthe A Andreae, Julie Wang
No abstract text is available yet for this article.
November 2014: Pediatrics
keyword
keyword
36108
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"